Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz

British Journal of Clinical Pharmacology

Volumn 60, Issue 1, 2005, Pages 32-34

  Dailly, Eric ^a   Allavena, Clotilde ^a   Raffi, François ^a   Jolliet, Pascale ^a  

^a HÔTEL DIEU   (France)

Author keywords

Efavirenz; Interaction; Lopinavir; Pharmacokinetics

Indexed keywords

EFAVIRENZ; LOPINAVIR; NUCLEOSIDE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; OXAZINES; PYRIMIDINONES; RITONAVIR;

EID: 21744452887     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02369.x     Document Type: Article

References (7)

1. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-9.
2. Ferré V, Allavena C, Poizot-Martin I, et al. Biks Study (Lopinavir/Ritonavir-Efavirenz combination): complete 24-week results. Antivir Ther 2003; 8(Suppl 1): S193.
3. Solas C, Poizot-Martin I, Drogoul MP, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol 2004; 57: 436-40.
4. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-9.
5. Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Biomed Sci Appl 2004; in press.
6. Dariosecq JM, Taburet AM, Girard PM. Interactions des antirétroviraux. In: The Infection VIH - Mémento Thérapeutique, 6th edn, eds. Dariosecq JM, Taburet AM, Girard PM. Rueil-Malmaison: Doin 2003; 134-205.
7. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002; 71: 57-67.